Avian adenovirus vector CELO-TK displays anticancer activity in human cancer cells and suppresses established murine melanoma tumors

Cancer Gene Therapy

Volumn 12, Issue 7, 2005, Pages 617-626

  Shashkova, Elena V ^a   Cherenova, Lubov V ^b   Kazansky, Dmitry B ^c   Doronin, Konstantin ^d  

^a ALL RUSSIA RESEARCH INSTITUTE OF AGRICULTURAL BIOTECHNOLOGY   (Russian Federation)

^b GAMALEYA RESEARCH INSTITUTE OF EPIDEMIOLOGY AND MICROBIOLOGY   (Russian Federation)

^c N N BLOKHIN RUSSIAN CANCER RESEARCH CENTER   (Russian Federation)

^d SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adenovirus; CELO virus; Experimental melanoma; Genetic vectors; Transduced suicide gene

Indexed keywords

ADENOVIRUS VECTOR; GANCICLOVIR; NEUTRALIZING ANTIBODY; PRODRUG; THYMIDINE KINASE;

ADENOVIRUS 5; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; AVIADENOVIRUS; CANCER CELL; CHICK EMBRYO LETHAL ORPHAN VIRUS; CONTROLLED STUDY; CROSS REACTION; DRUG ACTIVATION; DRUG EFFICACY; EGFP GENE; EMBRYO; FEMALE; GENE EXPRESSION; GENE TARGETING; GENETIC TRANSDUCTION; HERPES SIMPLEX VIRUS 1; HSV TK GENE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; SURVIVAL TIME; TUMOR CELL CULTURE; TUMOR GROWTH; VIRAL GENE DELIVERY SYSTEM; VIRION; VIRUS GENE; VIRUS GENOME; VIRUS INFECTION;

ANIMALS; CELL LINE, TUMOR; FEMALE; FOWL ADENOVIRUS A; GENE THERAPY; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; HUMANS; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; SIMPLEXVIRUS; SKIN NEOPLASMS; THYMIDINE KINASE; TRANSDUCTION, GENETIC; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ADENOVIRIDAE; AVIAN ADENOVIRUS; FOWL ADENOVIRUS 1; HUMAN ADENOVIRUS TYPE 5; HUMAN HERPESVIRUS 1; MURINAE;

EID: 22044442536     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700822     Document Type: Article

References (55)

1. McCormick F. Cancer gene therapy: fringe or cutting edge? Nat Rev Cancer. 2001;1:130-141.
2. Pearson S, Jia H, Kandachi K. China approves first gene therapy. Nat Biotechnol. 2004;22:3-4.
3. Kay MA, Glorioso JC, Naldini L. Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics. Nat Med. 2001;7:33-40.
4. Kootstra NA, Verma IM. Gene therapy with viral vectors. Annu Rev Pharmacol Toxicol 2003;43:413-439.
5. Both GW. Xenogeneic adenovirus vectors. In: Curiel DT, Douglas JT, eds. Adenoviral Vectors for Gene Therapy. New York, NY: Academic Press; 2001:447-479.
6. Loser P, Huser A, Hillgenberg M, et al. Advances in the development of non-human viral DNA-vectors for gene delivery. Curr Gene Ther. 2002;2:161-171.
7. Michou AI, Lehrmann H, Saltik M, et al. Mutational analysis of the avian adenovirus CELO, which provides a basis for gene delivery vectors. J Virol. 1999;73:1399-1410.
8. Laver WG, Younghusband HB, Wrigley NG. Purification and properties of chick embryo lethal orphan virus (an avian adenovirus). Virology. 1971;45:598-614.
9. Logunov DY, Ilyinskaya GV, Cherenova LV, et al. Restoration of p53 tumor-suppressor activity in human tumor cells in vitro and in their xenografts in vivo by recombinant avian adenovirus CELO-p53. Gene Therapy. 2004;11: 79-84.
10. Hyer RN, Howell MR, Ryan MA, et al. Cost-effectiveness analysis of reacquiring and using adenovirus types 4 and 7 vaccines in naval recruits. Am J Trop Med Hyg. 2000;62:613-618.
11. Cetron MS, Marfin AA, Julian KG, et al. Yellow fever vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2002. MMWR Recomm Rep. 2002;51:1-11.
12. Harper SA, Fukuda K, Uyeki TM, et al. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2004;53:1-40.
13. Weiss RA. Adventitious viral genomes in vaccines but not in vaccinees. Emerg Infect Dis. 2001;7:153-154.
14. Tree JA, Richardson C, Fooks AR, et al. Comparison of large-scale mammalian cell culture systems with egg culture for the production of influenza virus A vaccine strains. Vaccine. 2001;19:3444-3450.
15. Freeman SM, Abboud CN, Whartenby KA, et al. The "bystander effect": tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res. 1993;53:5274-5283.
16. Cherenova LV, Logunov DY, Shashkova EV, et al. Recombinant avian adenovirus CELO expressing the human interleukin-2: characterization in vitro, in ovo and in vivo. Virus Res. 2004;100:257-261.
17. Doronin K, Toth K, Kuppuswamy M, et al. Tumor-specific, replication-competent adenovirus vectors overexpressing the adenovirus death protein. J Virol. 2000;74:6147-6155.
18. Mittereder N, March KL, Trapnell BC. Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy. J Virol. 1996;70:7498-7509.
19. Fallaux FJ, van der Eb AJ, Hoeben RC. Who's afraid of replication-competent adenoviruses? Gene Therapy. 1999;6: 709-712.
20. Lichtenstein DL, Toth K, Doronin K, et al. Functions and mechanisms of action of the adenovirus E3 proteins. Int Rev Immunol. 2004;23:75-111.
21. Washietl S, Eisenhaber F. Reannotation of the CELO genome characterizes a set of previously unassigned open reading frames and points to novel modes of host interaction in avian adenoviruses. BMC Bioinformatics. 2003;4:55.
22. Shenk T. Adenoviridae: the viruses and their replication. In: Knipe DM, Howley PM, eds. Fields Virology. Philadelphia, PA: Lippincott, Williams & Wilkins; 2001:2265-2300.
23. Davison AJ, Benko M, Harrach B. Genetic content and evolution of adenoviruses. J Gen Virol. 2003;84:2895-2908.
24. Chiocca S, Kurzbauer R, Schaffner G, et al. The complete DNA sequence and genomic organization of the avian adenovirus CELO. J Virol. 1996;70:2939-2949.
25. Hess M, Cuzange A, Ruigrok RW, et al. The avian adenovirus penton: two fibres and one base. J Mol Biol. 1995;252:379-385.
26. Tan PK, Michou AI, Bergelson JM, et al. Defining CAR as a cellular receptor for the avian adenovirus CELO using a genetic analysis of the two viral fibre proteins. J Gen Virol. 2001;82:1465-1472.
27. Bett AJ, Krougliak V, Graham FL. DNA sequence of the deletion/insertion in early region 3 of Ad5 d1309. Virus Res. 1995;39:75-82.
28. Springer CJ, Niculescu-Duvaz I. Prodrug-activating systems in suicide gene therapy. J Clin Invest. 2000;105:1161-1167.
29. Rubsam LZ, Boucher PD, Murphy PJ, et al. Cytotoxicity and accumulation of ganciclovir triphosphate in bystander cells cocultured with herpes simplex virus type 1 thymidine kinase-expressing human glioblastoma cells. Cancer Res. 1999;59:669-675.
30. Voskoglou-Nomikos T, Baral SD, Seymour LK. The role of in vitro cell line, human xenograft, and mouse allograft models in cancer drug development. In: Budman DR, Calvert AH, Rowinsky EK. eds. Handbook of Anticancer Drug Development. Baltimore. MD: Lippincott Williams & Wilkins; 2003:129-147.
31. Peterson JK, Houghton PJ. Integrating pharmacology and in vivo cancer models in preclinical and clinical drug development. Eur J Cancer. 2004;40:837-844.
32. Fillat C, Carrio M, Cascante A, et al. Suicide gene therapy mediated by the Herpes Simplex virus thymidine kinase gene/Ganciclovir system: fifteen years of application. Curr Gene Ther. 2003;3:13-26.
33. Pavlovic J, Nawrath M, Tu R, et al. Anti-tumor immunity is involved in the thymidine kinase-mediated killing of tumors induced by activated Ki-ras(G12V). Gene Therapy. 1996;3:635-643.
34. Ramesh R, Marrogi AJ, Munshi A, et al. In vivo analysis of the 'bystander effect': a cytokine cascade. Exp Hematol. 1996;24:829-838.
35. Francois A, Eterradossi N, Delmas B, et al. Construction of avian adenovirus CELO recombinants in cosmids. J Virol. 2001;75:5288-5301.
36. Glotzer JB, Saltik M, Chiocca S, et al. Activation of heat-shock response by an adenovirus is essential for virus replication. Nature. 2000;407:207-211.
37. Mesnil M, Piccoli C, Tiraby G, et al. Bystander killing of cancer cells by herpes simplex virus thymidine kinase gene is mediated by connexins. Proc Natl Acad Sci USA. 1996;93:1831-1835.
38. Lehrmann H, Gotten M. Characterization of CELO virus proteins that modulate the pRb/E2F pathway. J Virol. 1999;73:6517-6525.
39. Kumin D, Hofmann C, Rudolph M, et al. Biology of ovine adenovirus infection of nonpermissive cells. J Virol. 2002;76:10882-10893.
40. Armentano D, Smith MP, Sookdeo CC, et al. E4ORF3 requirement for achieving long-term transgene expression from the cytomegalovirus promoter in adenovirus vectors. J Virol. 1999;73:7031-7034.
41. Grave L, Dreyer D, Dieterle A, et al. Differential influence of the E4 adenoviral genes on viral and cellular promoters. J Gene Med. 2000;2:433-443.
42. Krasnykh V, Dmitriev I, Navarro JG, et al. Advanced generation adenoviral vectors possess augmented gene transfer efficiency based upon coxsackie adenovirus receptor-independent cellular entry capacity. Cancer Res. 2000;60:6784-6787.
43. Golumbek PT, Hamzeh FM, Jaffee EM, et al. Herpes simplex-1 virus thymidine kinase gene is unable to completely eliminate live, nonimmunogenic tumor cell vaccines. J Immunother. 1992;12:224-230.
44. Crittenden M, Gough M, Harrington K, et al. Expression of inflammatory chemokines combined with local tumor destruction enhances tumor regression and long-term immunity. Cancer Res. 2003;63:5505-5512.
45. Nathanson L. Malignant melanoma. In: Foley JF, Vose JM, Armitage JO, eds. Current Therapy in Cancer. 2nd ed. Philadelphia, PA: W.B. Saunders Company; 1999:245-254.
46. Boucher PD, Ostruszka LJ, Shewach DS. Synergistic enhancement of herpes simplex virus thymidine kinase/ganciclovir-mediated cytoxicity by hydroxyurea. Cancer Res. 2000;60:1631-1636.
47. Wildner O, Blaese RM, Morris JC. Therapy of colon cancer with oncolytic adenovirus is enhanced by the addition of herpes simplex virus-thymidine kinase. Cancer Res. 1999;59:410-413.
48. Hermiston T. Gene delivery from replication-selective viruses: arming guided missiles in the war against cancer. J Clin Invest. 2000;105:1169-1172.
49. Nanda D, Vogels R, Havenga M, et al. Treatment of malignant gliomas with a replicating adenoviral vector expressing herpes simplex virus-thymidine kinase. Cancer Res. 2001;61:8743-8750.
50. Freytag SO, Khil M, Stricker H, et al. Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer. Cancer Res. 2002;62:4968-4976.
51. Wodarz D. Gene therapy for killing p53-negative cancer cells: use of replicating versus nonreplicating agents. Hum Gene Ther. 2003;14:153-159.
52. Lambright ES, Amin K, Wiewrodt R, et al. Inclusion of the herpes simplex thymidine kinase gene in a replicating adenovirus does not augment antitumor efficacy. Gene Therapy. 2001;8:946-953.
53. Sauthoff H, Hu J, Maca C, et al. Intratumoral spread of wild-type adenovirus is limited after local injection of human xenograft tumors: virus persists and spreads systemically at late time points. Hum Gene Ther. 2003;14:425-433.
54. Wein LM, Wu JT, Kirn DH. Validation and analysis of a mathematical model of a replication-competent oncolytic virus for cancer treatment: implications for virus design and delivery. Cancer Res. 2003;63:1317-1324.
55. Sarma PS, Huebner RJ, Lane WT. Induction of tumors in hamsters with an avian adenovirus (CELO). Science. 1965;14:1108.